The UK National Institute of Clinical Excellence (NICE) have amended their prostate cancer guidelines and now recommend that the national standard for risk stratification for prostate cancer be based on the Cambridge Prognostic Groups (CPG) which was developed in the University of Cambridge Department of Surgery by Professor Vincent J Gnanapragasam and colleagues.
The updated guidance and details can be seen here-
https://www.nice.org.uk/guidance/ng131
https://www.nice.org.uk/guidance/ng131/chapter/Recommendations#staging
NICE now recommends that all newly diagnosed men in the UK should now be risk categorised by the CPG criteria and then appropriate treatment recommended
NICE recognised that the CPG 5 tier system significantly outperformed the model they have been using for the last 20 years and a change was in line with impending plans by the National Prostate Cancer Audit (NPCA) who were also shifting to the CPG criteria from 2022 onwards.
“Having the CPG model independently reviewed and adopted by NICE as the new standard of care in mainstream treatment is a testament to the robustness of the underpinning research and how Cambridge is transforming every day prostate cancer management for patients nationally and internationally” said Prof Gnanapragasam. “The CPG system has to date been tested and validated in over 250,000 men across 4 countries”.
